Acción BINV BIOINVENT INTERNATIONAL AB
Añadir a una lista
Para utilizar esta función debe ser un cliente o miembro.
ConéctateRegístrate

Otros idiomas BioInvent International AB

Acciones

BINV

SE0015244520

Diferido Nasdaq Stockholm
Otros sitios de cotización
 12:59:33 30/04/2024 		Varia. Cinco días. Varia. 1 de enero.
26 SEK +2,77 % Gráfico intradía de BioInvent International AB +11,59 % +37,13 %
30/04 BioInvent anuncia que evaluará la tecnología de Attana CI
24/04 BioInvent International AB (publ) presenta los resultados del primer trimestre finalizado el 31 de marzo de 2024 CI

Otros idiomas

Buscar
Ver los resultados
Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!
Inscripción 100% Gratuita
BioInvent evaluating Attana Technology
BioInvent Announces Evaluating Attana Technology
BioStock: BioInvent selected to present at ASCO in Chicago
BioInvent International AB, Interim report January-March 2024
BioInvent Q1 2024 - Approaching Catalysts
BioInvent to Present Clinical Data from its two leading assets at ASCO 2024
BioInvent International AB: Interim report January-March 2024
BioInvent International AB Reports Earnings Results for the First Quarter Ended March 31, 2024
BioInvent International AB publishes Annual Report 2023
BioStock: BioInvent deepens collaboration with MSD
BioInvent announces a new clinical trial collaboration and supply agreement with MSD to evaluate BI-1910, the company s second anti-TNFR2 antibody in combination with KEYTRUDA
BioInvent, Merck & Co. Unit Sign Clinical Trial, Supply Deal for Tumor Treatment as Add-On Therapy for Keytruda
BioInvent International : announces a new clinical trial collaboration and supply agreement with MSD to evaluate BI-1910, the company's second anti-TNFR2 antibody in combination with KEYTRUDA® (pembrolizumab)
BioInvent announces a new clinical trial collaboration and supply agreement with MSD to evaluate BI-1910, the company’s second anti-TNFR2 antibody in combination with KEYTRUDA® (pembrolizumab)
Notice to Annual General Meeting in BioInvent International AB
BioStock: BioInvent's CEO comments on the study success in China
BioInvent International, CASI Pharmaceuticals Report Positive Interim Phase 1 Data For BI-1206 In The Treatment Of Relapsed, Refractory Indolent Non-Hodgkin's Lymphoma In China
BioInvent International: CASI Pharmaceuticals Report Positive Interim Phase 1 Data For BI-1206 In The Treatment Of Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma In China
BioInvent International: CASI Pharmaceuticals Report Positive Interim Phase 1 Data For BI-1206 In The Treatment Of Relapsed/Refractory Indolent Non-Hodgkin’s Lymphoma In China
BioInvent International AB Year-end report January 1, December 31, 2023
No hay resultados para esta búsqueda
Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Filtros

Buscar

Fecha de publicación

De

Hasta

  1. Bolsa de valores
  2. Acciones
  3. Acción BINV
  4. Noticias BioInvent International AB
  5. Otros idiomas